How has been the historical performance of Kabra Drugs?

Answer:The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a marginal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, peaking at 0.02 Cr in March 2020 and declining to zero thereafter. The company has incurred increasing total expenditures, which rose from 0.14 Cr in March 2019 to 1.72 Cr in March 2025, primarily driven by rising employee costs and other expenses. Operating profit has been negative throughout this period, with losses escalating from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The net profit has similarly deteriorated, moving from -0.16 Cr in March 2019 to -1.09 Cr in March 2025. The company's equity capital increased significantly to 23.71 Cr by March 2025, while total reserves improved to 0.95 Cr, indicating a shift from negative reserves in previous years. The cash flow from financing activities saw a notable inflow of 2.00 Cr in March 2024, contributing to a closing cash balance of 2.00 Cr, a significant increase from previous years.

Breakdown:
Kabra Drugs has not generated any net sales from March 2021 to March 2025, with only a slight revenue recorded in March 2019. The total operating income peaked at 0.02 Cr in March 2020 but has since fallen to zero. Expenditures have risen sharply, particularly in employee costs and other expenses, leading to a growing operating loss, which reached -1.08 Cr in March 2025. The net profit has also worsened, moving from -0.16 Cr in March 2019 to -1.09 Cr in March 2025. Despite these losses, the company's equity capital surged to 23.71 Cr by March 2025, and total reserves turned positive at 0.95 Cr. The cash flow from financing activities marked a significant inflow of 2.00 Cr in March 2024, resulting in a closing cash balance of 2.00 Cr, indicating some liquidity improvement amidst ongoing operational challenges.